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Abstract The nucleotide sequence of the monoclonal antibody
F124, specific for the preS2 region of the surface antigen of
hepatitis B virus, has been determined and an single-chain Fv
fragment (scFv) recombinant construction has been cloned and
expressed into the periplasmic region of Escherichia coli. The
recombinant antibody fragment contains a (Gly4Ser)3 linker
connecting the C-terminus of the heavy chain variable region
(VL) domain to the N-terminus of the light chain variable region
(VL) domain. A 23-residue peptide segment, containing a c-myc
marker for immunochemical detection of the scFv and hexahis-
tidine tag to facilitate its purification, was added C-terminal to
the VL domain. The scFv mimics the antibody in binding to the
native antigen in the form of recombinant hepatitis B surface
antigen (HBsAg) particles as well as to peptide fragments
carrying the viral epitope.
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1. Introduction
The major humoral immune response to hepatitis B virus
(HBV) is mounted against the hepatitis B surface antigen
(HBsAg), which is composed of three related membrane-
bound proteins, S, M and L, located in the lipid bilayer of
the viral envelope [1]. The proteins are translation products
from an open reading frame with three in-phase initiation
codons placed such that the M and L polypeptides share
the S sequence (224 residues) at their C-terminal moieties.
The M protein carries an additional 55 residues, known as
the preS2 region (residues 120^174), in a position N-terminal
to the S sequence, while the L protein carries the preS1 region,
comprising 108 or 119 residues depending on the serotype, in
a position N-terminal to the M sequence.
F124 is an anti-HBsAg monoclonal antibody (isotype IgG1/
U) which was obtained by immunisation of BALB/c mice with
HBV particles, serotype ay, puri¢ed from the plasma of a
chronic carrier [2]. The antibody recognises an epitope that
includes residue 126 of the preS2 region since it binds less well
to the peptide segment 120^153 derived from the adw sero-
type, where Thr-126 from the immunising ay serotype is sub-
stituted by alanine [3]. Furthermore, the epitope includes the
preS2 glycan N-linked to Asn-123 since removal of carbohy-
drate from HBsAg particles carrying proteins S and M sig-
ni¢cantly reduces F124 binding [4]. Finally, the epitope is
restricted essentially to the N-terminal region of preS2 since
its binding to the peptide fragment 120^145 is not compro-
mised by the presence of F376, a monoclonal antibody recog-
nising the segment 132^145 [5]. As a part of our programme
of structural studies on the antigenic recognition of HBsAg,
we report here the nucleotide sequence of the gene segments
encoding the variable domains of F124, and describe the clon-
ing and expression of a single-chain Fv construction of the
antibody. We also compare the antigen-binding properties of
single-chain Fv fragment (scFv) F124 with those of the native
antibody.
2. Materials and methods
2.1. Sources of antibody and antigens
The monoclonal anti-HBV antibody, F124 (CNCM I-470, 03/07/
1985), was puri¢ed from ascitic £uids by ammonium sulfate precip-
itation and chromatography on DEAE-Sephacel, and the Fab was
obtained by papain digestion. Recombinant lipoprotein particles,
r-HBsAg, expressed in Chinese hamster ovary cells [6] and bearing
the preS2 and S domains (serotype ayw), were purchased from Pasteur
MeŁrieux. PreS2 peptides used in competitive binding studies were
120^132 (subtype ayw): MQWNSTTFHQTLQ (Neosystem); 120^
145 (subtype ayw): MQWNSTTFHQTLQDPRVRGLYFPAGG;
and 148^174 (subtype adw2): SGTVNPAPNIASHISSISARTGD-
VALN (provided by O. Si¡ert, Institut Pasteur).
2.2. RNA extraction and cDNA synthesis
Total RNA was isolated from 107 F124-expressing hybridoma cells
by the acid guanidinium thiocyanate-phenol-chloroform method [7].
cDNA synthesis was performed using oligo dT 15-mer primer (Boeh-
ringer), Moloney murine leukemia virus reverse transcriptase (Gibco),
RNase inhibitor (Boehringer) and a mixture of the four deoxyribonu-
cleotides.
2.3. Ampli¢cation of the variable domain genes
PCR ampli¢cation was carried out using Taq DNA polymerase
(Cetus Perkin Elmer). The heavy chain variable region (VH) gene
was ampli¢ed with the primers VH IIA (5P-GAG GTC CAG CTC
GAG CAG TCT GGA CC-3P) and CH (5P-GGC AGC GAT CCA
GGG GCC AGT GG-3P) (G. Orsanoudakis and P. Lafaye, personal
communication), while the light chain variable region (VL) gene was
ampli¢ed with the primers VU LC7 (5P-CCA GTT CCG AGC TCG
TGA TGA CAC AGT CTC CA-3P) and CU (5P-GCG CCG TCT
AGA ATT AAC ACT CAT TCC TGT TGA A-3P) [8]. PCR products
were gel puri¢ed and ligated into the pMOSBlue T-vector (Amer-
sham). MOS Blue E. coli bacteria were transformed and selected by
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K-complementation screening, and the plasmid DNA from several
positive clones was analysed by restriction digestion. Double-stranded
nucleotide sequencing was performed by the dideoxy chain-termina-
tion method (Promega) from multiple independent clones. In order
to correct the 5P end of VH and VL for the possible sequence
di¡erences with the primers, the N-terminal amino acid sequence
was determined for both chains (Laboratoire de MicroseŁquenc°age
des ProteŁines, Institut Pasteur, Paris). Analysis of the nucleotide se-
quence was performed with FASTA 3.1 [9] and DNAPLOT (http://
www.genetik.uni-koeln.de/dnaplot/). The VL and VH nucleotide se-
quences of F124 have been deposited at the EMBL Nucleotide Se-
quence Database with accession codes AJ012372 and AJ012373, re-
spectively.
2.4. Expression vector and construction of scFv F124
The expression vector chosen for scFv F124 was pAB1 [10] which is
based on pUC119. It contains a multiple cloning site preceded by a
pelB leader sequence, and followed by a c-myc epitope tag and a six-
histidine tag for immobilised metal a⁄nity chromatography puri¢ca-
tion.
VH and VL cDNA isolated from the F124 hybridoma were joined
by a two step fusion PCR using an oligonucleotide coding for the
(Gly4Ser)3 linker. The VH and VL sense primers were corrected on the
basis of the amino acid sequences. Accordingly, VH was ampli¢ed
with the primers S¢I (5P-TAC TCG CGG CCC AAC CGG CCA
TGG CCG AGG TVC AGC TGC ARC ART CTG G-3P) and VH-
linker (5P-AGA GCC ACC TCC GCC TGA ACC GCC TCC ACC
TGC AGA GAC AGT GAC CAG-3P). VL was ampli¢ed with the
primers VL-linker (5P-GGC GGA GGT GGC TCT GGC GGT GGC
GGA TCG GAC ATG GTG CTV ACM CAR TCT-3P) and NotI (5P-
GAT ATG AGA TAC TGC GGC CGC CCG TTT TAT TTC CAA
CTT TGT CCC-3P) (Genset). The ¢rst PCR step introduced a 3P-
terminal (Gly4Ser)2-coding sequence into VH with the VH-linker pri-
mer, and a 5P-terminal (Gly4Ser)2-coding sequence into VL with the
VL-linker primer. The puri¢ed ampli¢cation products of VL and VH
were used for the second step fusion PCR with the primers S¢I and
NotI. The resulting PCR fragment coding for the single chain mole-
cule was subcloned (using restriction sites S¢I and NotI) into the
bacterial expression vector pAB1 and sequenced.
2.5. Expression, puri¢cation and oligomerisation studies of scFv F124
E. coli TG1 cells transformed with pAB1-F124 were grown in 2YT,
0.1% glucose and 100 Wg/ml ampicillin in a shaking £ask at 37‡C to an
optical density of 0.8 at 600 nm, and induced by the addition of 1 mM
IPTG (ICN). After 3 h of induction at 24‡C, cells were harvested and
resuspended in 20 mM Tris-HCl at pH 8 and 0.7 M sucrose. Solutions
of lysozyme (Sigma) and EDTA were added to give ¢nal concentra-
tions of 0.22 mg/ml and 10 mM, respectively. After incubating for 30
min at 4‡C, cells were harvested and the supernatant was dialysed
against PBS. The protein was loaded onto a Ni2-charged His-Bind
Resin (Novagen), washed with 20 mM Tris at pH 7.9, 0.5 M NaCl
and 5 mM imidazole, and then eluted with 20 mM Tris at pH 7.9,
0.5 M NaCl and 200 mM imidazole. The protein was further puri¢ed
using gel ¢ltration chromatography on a Superdex 200 HR 10/30
column (Pharmacia).
Monomeric and multimeric species of the puri¢ed scFv were sepa-
rated by gel ¢ltration on a Superdex 200 HR 10/30 column in PBS, at
a £ow rate of 0.5 ml/min. The column was calibrated with Chroma-
tography Standards (Bio-Rad). The stability of puri¢ed monomer and
dimer species was monitored by size exclusion HPLC on a Superdex
200 column.
2.6. Competitive binding of scFv to r-HBsAg
Inhibition of binding of the F124 Fab or IgG to r-HBsAg in the
presence of scFv was measured by ELISA. Wells of an ELISA plate
(Nunc-immunomodules) were coated with recombinant particles (0.1
Wg/100 Wl in PBS) and incubated overnight at 4‡C. A mixture of a
constant amount of Fab (10 Wg/ml) or IgG (0.1 Wg/ml) and various
amounts of scFv diluted in PBS, supplemented with 0.02% BSA and
0.05% Tween 20, was then added to the wells for 1 h of incubation at
37‡C. Residual binding of Fab or IgG to r-HBsAg was measured
from the absorbance at 405 nm after the addition of alkaline-phos-
phatase-conjugated anti-mouse Fab-speci¢c (Sigma) or Fc-speci¢c
(ICN) IgG, respectively, followed by p-nitrophenyl phosphate disodi-
um (Sigma).
2.7. Competitive binding of scFv and IgG to peptides
Inhibition of binding of scFv or entire IgG to r-HBsAg in the
presence of three peptides spanning the preS2 region (see Section
2.1) was analysed by ELISA. Wells were coated with 0.1 Wg of
r-HBsAg dissolved in PBS and incubated 2 h at 37‡C. Each peptide
was then mixed at various concentrations with a constant amount of
scFv (0.1 Wg/ml) or IgG (0.05 Wg/ml) in PBS supplemented with 0.02%
BSA and 0.05% Tween 20. After 30 min of incubation at 37‡C, 100 Wl
of each mixture were transferred to the wells of the ELISA plate
previously coated with the recombinant antigen. The monoclonal anti-
body anti c-myc 9E10 was added after a further 20 min at 37‡C for
the scFv trials and incubated for 1 h at 37‡C. Binding to antigen-
coated wells by 9E10-linked scFv or IgG was then detected by the
addition of biotin-conjugated anti-mouse IgG (Vector), then strepta-
vidin-horseradish peroxidase (Vector), followed by 2,2P-azinodi[3-eth-
ylbenzthiazoline sulfonate] (Kierkegaard and Perry Laboratories) as
colour-development reagent. The absorbance was measured at 405
nm.
3. Results
3.1. Analysis of VH and VL sequences
The nucleotide sequence obtained from the rearranged V
region genes of F124 is shown in Fig. 1. Sequence analysis
of the VH region (Fig. 1A) showed that it belongs to the
mouse H-chain subgroup IIA of Kabat [11]. It shares 97.5%
sequence identity with the germline gene, M104E, a member
of the J558 VH subfamily. Seven base pair changes are ob-
served: four are silent mutations located in the framework
region (FR)-H1, one is placed within the complementarity
determining region (CDR)-H2, resulting in the replacement
Gly-58CSer, and two are located in the 3P-terminal codon
94 of the VH gene segment, giving rise to the change Arg-
94CAsn. The CDR-H3 comprises 10 codons contributed by
the D gene segment DFL16.1, used in reading frame 3, and
the 5P end of the JH3 segment (Fig. 1B). Three nucleotides are
changed within CDR-H3, resulting in the following changes:
Asp-95CTyr and Thr-99CAsn, from mutations within the D
gene segment, and Gly-100ACTrp, from a mutation in JH.
Sequence analysis of the VL region showed that it belongs
to the mouse U chain subgroup III of Kabat [11]. The VU gene
segment of F124 exhibits 97.9% homology with the
MMY15968 germline sequence, belonging to the VU21 family
(Fig. 1C) and is joined to the JU4 segment (Fig. 1D). Six base-
pair di¡erences were observed with respect to the germline
sequence, two of which are silent mutations. This leads to
amino acid replacements in FR-L1 (Met-2CIle), CDR2-L2
(Val-50CAla and Lys-55CGlu) and CDR-L3 (Gln-
90CArg). No mutations are present in the sequence contrib-
uted by JU4.
3.2. Cloning, bacterial production and puri¢cation of scFv
The scFv was constructed by introducing the 15-residue
linker, (Gly4Ser)3, connecting the C-terminus of VH to the
N-terminus of VL. The recombinant protein also carries a
23-residue peptide segment, AAAEQKLISEEDLNGAAH-
HHHHH, in position C-terminal to VL. This sequence con-
tains a c-myc marker (underlined residues) recognised by
monoclonal antibody 9E10 [12] and a hexahistidine tail to
facilitate puri¢cation. A diagram of the construction is shown
in Fig. 2. Since expression of scFv F124 was toxic for bac-
teria, di¡erent strains and induction times were tested. Opti-
mum results were obtained using TG1 cells in the presence of
0.1% glucose during the growth period and an induction of 3 h
at 24‡C with 1 mM IPTG. Fig. 3A shows the response of
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Fig. 1. Nucleotide and encoded amino acid sequences for the variable domain genes of F124. The amino acid residue numbering and the CDR
limits are according to Kabat [11]. Di¡erences with germline sequences and the corresponding encoded amino acid sequences are also shown.
A: VH domain compared with VH germline M104E. B: CDR-H3 and FR-H4 compared with DFL16.1 and JH3 gene segments. The three
5P-terminal nucleotides of DFL16.1, which are assumed to be deleted during somatic recombination, are shown in small letters. C: VL domain
compared with germline VU MMY15968 germline. D: FR-L4 compared with JU4.
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bacteria to di¡erent incubation times in the presence of IPTG.
In the presence of glucose and absence of IPTG no expression
of scFV occurred. During the ¢rst 4^5 h of induction at 24‡C,
scFv was recovered in the periplasm. After 24 h, however, the
cells were weakened and scFv was released into the growth
medium. Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) analysis of fractions coming from
IMAC chromatography (Fig. 3B) showed that elution of the
protein began at 60 nM imidazole in quite pure form (veri¢ed
with the anti-c-myc antibody 9E10). Gel ¢ltration chromatog-
raphy on a Superdex HR eliminated all impurity. The yield of
puri¢ed recombinant scFv was 0.8 mg per litre of culture
medium. Although the molecular weight was calculated
from the sequence to be 28.7 kDa, SDS-PAGE analysis
gave an apparent molecular weight of approximately 33 kDa.
3.3. scFv monomer-dimer equilibrium
Equilibrium between the monomer and the dimer, the prin-
cipal species present in the solution, was studied by size-ex-
clusion HPLC (data not shown). The monomer and the dimer
were ¢rst separated and concentrated, and then analysed sep-
arately by gel ¢ltration for interconversion between monomer
and dimer at various time intervals in PBS at 4‡C. At a pro-
tein concentration lower than 200 Wg/ml, the distribution was
analysed at times 0, 6, 15 and 28 days, while at higher protein
concentrations (1.5 mg/ml and 2.2 mg/ml), the analysis was
made at 0, 2, 6 and 15 days. At low protein concentrations,
the monomer showed no tendency to aggregate over 28 days,
while the dimer slowly dissociated. At high protein concen-
trations equilibrium was achieved at a monomer/dimer ratio
of 3:1. Thus, while dilute solutions of the monomer are stable,
aggregation becomes more important at higher concentra-
tions.
3.4. Competitive binding of scFv
F124 recognises an epitope localised at the N-terminal part
of the M protein and containing the preS2 residue 126 [3]. The
recombinant scFv F124 construction we describe here mimics
the antigenic speci¢city of the native antibody since it inhibits
the binding of both the Fab and IgG to r-HBsAg in a dose-
dependent manner (Fig. 4). Although the conjugated anti-
mouse Fc-speci¢c IgG did not bind to scFv F124, the con-
jugated anti-mouse Fab-speci¢c IgG did show a small non-
speci¢c binding to the construction (data not shown), thus
explaining the small di¡erences observed between the two
curves obtained with the Fab and the entire IgG.
Competitive binding to r-HBsAg by scFv or IgG in the
presence of preS2 peptides were also measured (Fig. 5). Pep-
tides 120^132 and 120^145 inhibit the binding of scFv or IgG
to r-HBsAg (coated on the ELISA plate) in a dose-dependent
manner, while the control peptide 148^174 exhibits no inhib-
ition of binding. Both the IgG and scFv bound 120^145 more
e¡ectively than 120^132, suggesting the larger peptide main-
tains the correct conformation of the epitope more e⁄ciently
for recognition by F124. A similar observation has been made
elsewhere for a monoclonal antibody recognising the preS2
FEBS 21328 30-12-98
Fig. 3. Production and puri¢cation (using a Ni2-charged column)
of scFv F124 carrying a c-myc marker and a hexahistidine tag. A:
Western blot of cytoplasmic expression of scFv in the absence of
(3IPTG) or presence (+IPTG) of induction. The scFv was detected
using the 9E10 anti-c-myc antibody and an alkaline phosphatase-
conjugated anti-mouse IgG antibody (substrate BCIP/NBT). B: 12%
SDS-PAGE revealed by Coomassie staining of puri¢ed scFv F124.
Lanes: 1, molecular standards; 2, periplasmic fraction containing
the scFv; 3, £ow-through; 4, washing with 5 mM imidazole; 5, elu-
tion with 60 mM imidazole; 6, elution with 200 mM imidazole.
Fig. 2. Schematic presentation of the genetic construction of ScFv
F124.
Fig. 4. Inhibition of the binding of Fab and IgG to r-HBsAg by
scFv.
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region 130^145; 120^145 was more e¡ectively bound than
132^145 [13].
4. Discussion
The scFv construction of F124, which was recovered from
the periplasm of E. coli with good yields, is functional since it
competes with F124 IgG and Fab for binding to antigen. As is
frequently observed with scFv constructions, that of F124
forms dimers and higher multimeric species, even at moderate
protein concentrations.
The sequence of F124 has allowed us to identify the V, D
and J gene segments used during somatic recombination to
create genes coding for the complete VH and VL domains of
the antibody, and to locate nucleotide mutations with respect
to the germline sequence. Of the 16 nucleotide changes, six are
silent mutations: four in the VH domain and two in the VL
domain. The remaining nucleotide mutations give rise to ¢ve
amino acid changes in the VH domain and four amino acid
changes in the VL domain. All but two of these (Asn-94 in VH
and Met-2 in VL) lie within the CDR de¢ned by Kabat [11].
The heavy chain mutation Ile-2CMet is the only amino acid
change in F124 that is buried in known 3-dimensional struc-
tures of closely homologous VH domains. This conservative
change should be easily accommodated, however, since the
side-chain volumes of these two hydrophobic, aliphatic resi-
dues are essentially identical [14]. The amino acid change Arg-
94CAsn in VH might have arisen during somatic recombina-
tion since codon 94 shares nucleotides from the VH and D
gene sequences (Fig. 1B). The codon sequence could thus have
arisen from imprecise joining between the two gene segments,
the ¢rst nucleotide being contributed by the VH gene, and the
second and third nucleotides by DFL16.1. The amino acid
mutation, Gly-100ACTrp, might also have arisen during so-
matic rearrangement of the D and JH segments (a deletion and
an N-insertion), but hypermutation appears an equally prob-
able alternative given that only one nucleotide is changed
(Fig. 1B).
Crystallographic studies on immunoglobulins have shown
that, with the exception of CDR-H3, the structure of the
hypervariable loops that form the antigen-binding site is lim-
ited to a small number of canonical conformations [15,16].
Although the number of possible permutations of CDR can-
onical conformations is signi¢cant (300), analysis of immuno-
globulins in the Kabat Data Base [11] has shown that the
immune system exploits only a small fraction of this potential
repertoire [17]. Indeed, just 10 CDR permutations from all
possible combinations were found to account for 86.9% of
the antibodies with known antigen speci¢city in the data
base. Furthermore, a correlation was detected between the
particular CDR combination and the nature of the speci¢c
antigen (protein, peptide, polysaccharide, nucleic acid or hapt-
en). Based on the amino acid sequence of F124, assignments
can be made for the CDR canonical conformations; CDR-
H1: canonical conformation 1; CDR-H2: 2; CDR-L1: 3;
CDR-L2: unique; CDR-L3: 1 [15]. Antibodies using this per-
mutation are speci¢c exclusively for proteins or surface anti-
gens [17] and thus corresponds to the expected character of
the epitope on HBsAg recognised by F124.
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